Nobivac Tricat Trio, lyophilisate and solvent for suspension for injection, for cats

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Viambatanisho vya kazi:

Feline calicivrus, strain f9 live attenuated; Feline herpes virus type 1, strain g2620a live attenuated; Feline panleucopenia virus, strain mw-1 live attenuated

Inapatikana kutoka:

Intervet Ireland Limited

ATC kanuni:

QI06AD04

INN (Jina la Kimataifa):

Feline calicivrus, strain f9 live attenuated; Feline herpes virus type 1, strain g2620a live attenuated; Feline panleucopenia virus, strain mw-1 live attenuated

Kipimo:

.

Dawa fomu:

Lyophilisate and solvent for suspension for injection

Dawa ya aina:

POM: Prescription Only Medicine as defined in relevant national legislation

Kundi la matibabu:

Cats

Eneo la matibabu:

feline panleucopenia virus / parvovirus + feline rhinotracheitis virus + feline calicivirus

Matibabu dalili:

Immunological - Live Vaccine

Idhini hali ya:

Authorised

Idhini ya tarehe:

2007-02-28

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Tricat Trio, lyophilisate and solvent for suspension for
injection, for cats
Nobivac RCP (AT, DE)
Nobivac Tricat Novum (ES)
Nobivac Tricat Novum vet (SE)
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each dose (1 ml) of reconstituted vaccine contains:
ACTIVE SUBSTANCES
:
Live attenuated feline calicivirus, strain F9:

10
4.6
PFU
1
;
Live attenuated feline rhinotracheitis virus, strain G2620A:

10
5.2
PFU
1
;
Live attenuated feline panleucopenia virus, strain MW-1:

10
4.3
CCID
50
2
.
1
PFU: Plaque-Forming Units
2
CCID
50
:
Cell Culture Infectious Dose 50%
EXCIPIENTS:
QUALITATIVE
COMPOSITION OF EXCIPIENTS AND OTHER CONSTITUENTS_ _
_ _
Lyophilisate:
_ _
Disodium phosphate dihydrate
_ _
Hydrolysed gelatin
_ _
Pancreatic digest of casein
_ _
Sorbitol
Solvent:
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Water for injections
Lyophilisate: off -white pellet.
Solvent: clear colourless solution.
3.
CLINICAL INFORMATION
3.1.
TARGET SPECIES
Cats.
3.2.
INDICATIONS FOR USE FOR EACH TARGET SPECIES
Active immunisation of cats:
−
to reduce the clinical signs caused by infection with feline
calicivirus (FCV) and feline
rhinotracheitis virus (FVR),
−
to prevent the clinical signs, leucopenia and virus excretion caused
by infection with feline
panleucopenia virus (FPLV).
Onset of immunity: for FCV and FVR: 4 weeks; for FPLV: 3 weeks.
Duration of immunity for FCV and FVR: 1 year; for FPLV: 3 years.
3.3.
CONTRAINDICATIONS
See section 3.7
3.4.
SPECIAL WARNINGS
Vaccinate healthy animals only.
Maternal antibodies, which may persist up to the age of 9-12 weeks,
can have a negative influence on
the efficacy of vaccination. In the presence of maternal antibodies,
vaccination may not completely
prevent the clinical signs, leucopenia and virus excretion following
an FPLV infection. In such cases
where a relatively high level of maternally derived antibodies is
expected, the vaccination schedule
should be planned accordingly.
3.5.